(Boursier.com) — The net turnover of Euromedis Laboratories amounts to 34 million euros for the financial year ending December 31, 2023 (38.8 million euros in 2022 at constant scope).
The gross margin (transport on purchases included) amounts to 9 ME for the 2023 financial year (6.1 ME in 2022), thus increasing from 15.7% to 26.5% on a constant basis.
The results for the year 2023 conclude a financial year marked operationally by the normalization of the cost of maritime freight which made it possible to support a drop in sales prices. The net profit share of the Laboratoires Euromedis group is 13.1 ME (-5.9 ME as of December 31, 2022). The exceptional operations linked to the sale of Paramat and the absorption of Laboratoires Euromedis respectively resulted in the recognition of an exceptional charge of 7.6 ME and financial income of 27.4 ME.
To the consequences of the war in Ukraine that the company has suffered since 2022, were added the effects of geopolitical instability in the Middle East observed in the 4th quarter of 2023 and which had a direct impact on transport costs on purchases. The volatility of the dollar linked to this unstable macroeconomic environment has made it difficult to manage currency purchases, which represents an important lever for margin optimization.
Outlook 2024
The 2024 financial year will see the reorganization of the company continue with the refocusing on its original business as well as new positive results from calls for tenders which will make it possible to support the activity at a level at least comparable to that of the financial year over the first half of the year.
However, the uncertainties linked to the global geopolitical environment weighing on the evolution of energy prices, currencies and certain raw materials, should perhaps shift the profitability horizon planned for 2024 by a few months.
©2024 Boursier.com